UiPath Inc. today announced a preview of its upcoming Agent Builder tool as it outlined its vision to combine its expertise in robotic process automation with generative artificial intelligence models ...

UiPath delivered a beat-and-raise quarter and was promoted into a midcap index. Shares of automation software company UiPath ...

UiPath (PATH) has been resilient in the face of potential disruption from generative AI. At this point, it is fairly clear that the company isn’t a gen AI winner, but the business is looking rather ...

UiPath stock popped more than 26% on Friday, one day after the company released quarterly earnings that beat Wall Street's top- and bottom-line expectations. Stream NBC 5 for free, 24/7, wherever you ...

UiPath is moving beyond simple, rule-based bots toward "agentic automation." Partnerships are helping to drive scalability of this evolving business. UiPath’s focus on security and transparency could ...

Testing an AI agent for donor tissue screening at Evergen surfaces more than technical performance questions. The project ...

Despite my piece lambasting AI agent (over)hype, I am not anti-agent, even if "agentic" is low on my list of favorite buzzwords. I'm just pushing for more precision on the pros and cons - and use case ...

UiPath launches AI-based Medical Record Summarization tool, reducing processing time from 45 minutes to minutes. Powered by Google Cloud, the agent improves accuracy, saves 40 minutes per referral, ...

Figma went public at $33 last July and currently trades at approximately $37. UiPath went public at $56 in April 2021, but it ...

UiPath is evolving beyond robotic process automation into an AI-driven model, expanding its market and potentially unlocking margin expansion by automating complex processes. Both UiPath and Palantir ...